Answers are grounded in this paper and cite their sources.
A small molecule was under investigation as an inhibitor of glucosylceramide synthase (GCS) for potential use in Fabry disease. To support preclinical activities, a four-step synthesis was developed and used to prepared kilogram quantities of the drug substance. The new route features a scalable CDI-mediated Lossen rearrangement as a substitution for hazardous azide chemistry that was employed in the original route.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: